We could not find any results for:
Make sure your spelling is correct or try broadening your search.
This late-stage clinical trial company focuses on preventing inflammation and acute organ injury. It is developing a platform of new drugs to prevent inflammation in the kidneys, liver and lungs...
TORONTO, Canada -- November 5, 2020 -- InvestorsHub NewsWire -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that...
TORONTO, Ontario, CANADA -- October 16, 2020 -- InvestorsHub NewsWire -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF...
TORONTO, Canada -- June 8, 2020 -- InvestorsHub NewsWire -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company...
TORONTO, Canada -- May 8, 2020 -- InvestorsHub NewsWire -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company...
TORONTO, Canada -- April 24, 2020 -- InvestorsHub NewsWire -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company...
Arch Biopartners Hires d3 Medicine to Develop a Human Trial for Brain Tumor Targeting Technology TORONTO, ONTARIO--(Marketwired - May 29, 2014) - Arch Biopartners Inc (Arch) or (the Company...
Arch Biopartners Appoints Claude Allary to Board of Directors TORONTO, ONTARIO--(Marketwired - Apr 17, 2014) - Arch Biopartners Inc ("Arch" or the "Company") (CNSX:ACH)(OTCBB:FOIFF) announced...
Arch Biopartners Enters Option to License University of Cincinnati Patent for Treating Bacterial Respiratory Infections TORONTO, ONTARIO--(Marketwired - Mar 28, 2014) - Arch Biopartners Inc...
Arch Biopartners Completes Private Placement TORONTO, ONTARIO--(Marketwired - Mar 25, 2014) - Arch Biopartners Inc. ("Arch" or the "Company") (CNSX:ACH)(OTCBB:FOIFF) announced today it has...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.03 | -2.18181818182 | 1.375 | 1.445 | 1.345 | 7765 | 1.38717835 | CS |
4 | -0.1348 | -9.10933909988 | 1.4798 | 1.51 | 1.307 | 13096 | 1.42255023 | CS |
12 | 0.2849 | 26.8748231299 | 1.0601 | 1.5225 | 1.04 | 9607 | 1.3701445 | CS |
26 | 0.125 | 10.2459016393 | 1.22 | 1.5225 | 0.8925 | 9398 | 1.26429264 | CS |
52 | 0.535 | 66.049382716 | 0.81 | 1.88 | 0.7909 | 13692 | 1.33522026 | CS |
156 | -2.045 | -60.3244837758 | 3.39 | 4.13 | 0.72 | 13325 | 1.61965703 | CS |
260 | 0.62655 | 87.2085740135 | 0.71845 | 4.13 | 0.525 | 13363 | 1.51358122 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions